Eagle Asset Management Inc. Purchases Shares of 1,540,616 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Share on StockTwits

Eagle Asset Management Inc. purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 1,540,616 shares of the biopharmaceutical company’s stock, valued at approximately $23,894,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Virtus ETF Advisers LLC raised its holdings in Halozyme Therapeutics by 1.2% in the 2nd quarter. Virtus ETF Advisers LLC now owns 51,461 shares of the biopharmaceutical company’s stock valued at $884,000 after acquiring an additional 626 shares during the last quarter. Taylor Wealth Management Partners increased its holdings in shares of Halozyme Therapeutics by 0.4% during the 2nd quarter. Taylor Wealth Management Partners now owns 205,084 shares of the biopharmaceutical company’s stock worth $3,523,000 after buying an additional 735 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its holdings in shares of Halozyme Therapeutics by 25.2% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,800 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 967 shares during the last quarter. NumerixS Investment Technologies Inc increased its holdings in shares of Halozyme Therapeutics by 70.7% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 2,390 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 990 shares during the last quarter. Finally, Commonwealth Equity Services LLC increased its holdings in shares of Halozyme Therapeutics by 2.4% during the 2nd quarter. Commonwealth Equity Services LLC now owns 44,890 shares of the biopharmaceutical company’s stock worth $771,000 after buying an additional 1,050 shares during the last quarter. Institutional investors own 82.50% of the company’s stock.

Shares of HALO stock traded up $0.13 on Friday, reaching $16.87. 894,900 shares of the stock were exchanged, compared to its average volume of 868,255. The company has a quick ratio of 2.57, a current ratio of 2.89 and a debt-to-equity ratio of 0.05. Halozyme Therapeutics, Inc. has a 1-year low of $13.24 and a 1-year high of $17.79. The firm has a 50 day moving average of $15.70 and a two-hundred day moving average of $16.13. The stock has a market cap of $2.50 billion, a P/E ratio of -30.13 and a beta of 1.78.

HALO has been the subject of a number of research analyst reports. Barclays upgraded Halozyme Therapeutics from an “underweight” rating to an “equal weight” rating and dropped their price objective for the stock from $17.00 to $16.00 in a report on Tuesday, November 5th. ValuEngine downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 21st. BidaskClub downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 price objective for the company in a report on Thursday. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $20.50.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Featured Article: Sell-Side Analysts

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.